The study of gene expression regulation systems, transcriptional, post-transcriptional, and translational processes require in-depth knowledge of the structure and dynamics of protein–DNA and protein–RNA complexes. Furthermore, the discovery of the multiple roles played by different types of RNA, including within extracellular vesicles, has raised new questions about the systems responsible for stabilizing and transporting these RNAs. Over the years, numerous experimental approaches have been developed for the study of complexes between proteins and nucleic acids, both in terms of the type and degree of accuracy of the information they are able to provide. Furthermore, some techniques have proven suitable for monitoring dynamic processes, while others provide very high-resolution data.

Can humans regrow limbs? Researchers find SP6 and SP8 genes are vital for regeneration in axolotls and mice, creating a viral gene therapy that mimics salamander regrowth powers.

Systemic therapy targets in mesothelioma.

Recent changes to clinical practice have made modest improvements in 1– 2-year survival, but longer-term survival remains unchanged, and durable benefit is very rare.

Combining immunotherapy with chemotherapy, particularly with novel bispecific agents, may result in more therapeutic modalities being administered together in the first-line setting. The current evidence for second-line treatments is sparse.

New targeted-therapy strategies are promising. Early-phase clinical trials are showing signals of efficacy in mesotheliomas harboring MTAP loss or inactivation of the Hippo pathway.

Further studies will be needed to robustly confirm clinical benefit. sciencenewshighlights ScienceMission https://sciencemission.com/Mesothelioma

---

Mesothelioma is a rare cancer that has seen few incremental improvements in survival over the past two decades. However, a significantly improved understanding of the underlying biology has led to new therapeutic advances with the potential to improve clinical outcomes. In this review, we take a snapshot of the current systemic therapy research landscape, with our goal to forecast the trajectory of drug development for mesothelioma over the next half-decade. In our current census, we identify 106 active trials including systemic therapies: 20 (19%) are molecularly targeted, 26 (25%) include immunomodulation, and 12 (11%) combining immunotherapy with antiangiogenic therapies. Collectively, the landscape of therapeutic innovation for mesothelioma is expanding, bringing hope that improvements in life expectancy may follow.

Highlighting the potential of PTH1R receptor agonist therapy in autosomal dominant hypocalcemia type 1

https://doi.org/10.1172/JCI201759 In this Research Letter, Rajesh V. Thakker & team report on the use of Eneboparatide in mice with ADH1, which increased serum calcium levels without increasing urine calcium.

---

³Mary Lyon Centre, MRC Harwell, Harwell Science and Innovation Campus, Oxfordshire, United Kingdom.

⁴Endocrine Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA.

⁵William Harvey Research Institute, London School of Medicine, Queen Mary University of London, London, United Kingdom.

A promising cancer therapy, targeting infected tumors, is set for its first human trials as soon as May/June. This innovative approach shows potential for various solid cancers and could significantly impact treatment timelines, offering hope particularly for pancreatic cancer patients.

Read more

Dr. Janine Gaiha-Rohrbach, Ph.D. — Head of Global Medical Immunology, Biogen.

---

Preventing transplant loss doesn’t just save organs—it could eliminate hospitalizations, reduce lifelong medications, and transform millions of lives.

Dr. Janine Gaiha-Rohrbach, Ph.D. is a globally recognized leader in immunology and medical strategy, currently serving as Head of Global Medical Immunology at Biogen (https://www.biogen.com/).

With a PhD in Immunology and Virology from the University Hospital of Berne and extensive postdoctoral research at the Ragon Institute of Mass General Brigham, MIT, and Harvard, Dr. Gaiha-Rohrbach has dedicated her career to translating complex scientific advances into high-impact patient care.

Throughout her career, Dr. Gaiha-Rohrbach has driven innovation across diverse therapeutic areas, including HIV, hepatitis, NASH, and specialized immunology, leading multiple new product launches and shaping global strategies to expand patient access.